

# Routine immunization profile Republic of Moldova

## Progress towards achieving European Vaccine Action Plan goals, 2017

Goal	Indicator	Status	Goal	Indicator	Status
1	Sustain polio-free status <sup>a</sup> (Current risk)	Yes (Intermediate)	4	Meets vaccination coverage targets DTP3 national immunization coverage $\geq 95\%$ <sup>d</sup> $\geq 90\%$ DTP3 coverage achieved in $\geq 90\%$ of districts <sup>e</sup>	No No No
2	Measles elimination status <sup>b</sup>	Eliminated	5	Make evidence-based decisions about introduction of new vaccines <sup>*e,i</sup> NITAG made a recommendation about PCV NITAG made a recommendation about RV NITAG made a recommendation about HPV	Yes
	Rubella elimination status <sup>b</sup>	Eliminated			NNI NNI Yes
3	Control hepatitis B infection <sup>c</sup>	Validation pending	6	Achieve financial sustainability of the national immunization programme <sup>**c</sup>	Yes

\*New vaccines introduced or not introduced based on NITAG evidence-based recommendations

\*\*Country self-sufficient for procuring routine vaccines

## Demographic, income and health expenditure summary, 2017

Total Population <sup>f</sup>	4 051 212
Live births	40 877
Surviving infants	40 362
<5 years	213 070
<15 years	637 657
Neonatal mortality rate (per 1000 live births) <sup>f</sup>	11.6
Infant mortality rate (per 1000 live births) <sup>f</sup>	13.3
Number of districts <sup>e</sup>	44
GNI (per capita, in USD) <sup>g</sup>	2200
Health spending as % of total government expenditure <sup>g</sup>	12

## Immunization schedule, 2017<sup>e,i</sup>

Birth	BCG, HepB_Pediatric
2M	DTwPHibHepB, OPV, PCV, Rotavirus
4M	DTwPHibHepB, OPV, PCV, Rotavirus
6M	DTwPHibHepB, OPV
12M	MMR, PCV
2Y	DTwP, OPV
7Y	DT, MMR, OPV
15Y	MMR, Td
20Y	Td*

\*Repeats every 10 years




### Vaccine coverage estimates, 2013-2017<sup>d</sup>


	2013	2014	2015	2016	2017
BCG	96	97	97	97	96
HepB-BD	95	96	96	99	96
DTP1	86	94	88	94	91
DTP3	90	90	87	89	88
HepB3	91	92	88	90	89
Hib3	89	89	86	89	88
Pol3	92	92	88	91	90
PCV3	1	28	71	77	78
Rotac	65	69	62	70	65
RCV1	91	90	89	88	93
MCV1	91	90	89	88	93
MCV2	94	93	90	95	92

100 50 0 ND NR


### DTP3 reported coverage by subnational area<sup>†</sup>, 2017<sup>e</sup>



### MCV1 reported coverage by subnational area<sup>†</sup>, 2017<sup>e</sup>



### MCV2 reported coverage by subnational area<sup>†</sup>, 2017<sup>e</sup>



### Number of reported cases of vaccine-preventable diseases, 2013-2017<sup>e,i</sup>


	2013	2014	2015	2016	2017
Measles	27	2	0	0	0
Mumps	60	51	70	109	78
Rubella	0	0	0	0	0
Congenital rubella syndrome	0	0	0	0	0
Diphtheria	0	0	0	0	0
Tetanus	0	0	0	0	0
Pertussis	115	188	50	283	355
Hepatitis A	113	491	280	749	593
Varicella	12 076	11 279	10 902	14 312	10 526

### Surveillance with laboratory confirmation of cases, 2017<sup>e</sup>


Measles	Yes
Rubella	Yes
Congenital rubella syndrome	Yes
Rotavirus	Yes
Invasive meningococcal disease	Yes
Invasive pneumococcal disease	Yes
Invasive <i>Haemophilus influenzae</i> disease	Yes

Note: Case-based surveillance (with laboratory confirmation of cases) assessed for measles, rubella, and congenital rubella syndrome. Hospital-based sentinel surveillance and/or population-based surveillance (both with laboratory confirmation of cases) assessed for rotavirus, invasive meningococcal disease, invasive pneumococcal disease, and invasive *Haemophilus influenzae* disease.


### Number of reported measles, mumps and rubella cases<sup>e</sup> and MCV coverage estimates<sup>d</sup>, 2013-2017




### Number of reported diphtheria, tetanus and pertussis cases<sup>e</sup> and DTP3 coverage estimates<sup>d</sup>, 2013-2017




### Reported target population, reported number of DTP3 doses administered and DTP3 reported coverage<sup>e</sup>, 2013-2017



### Percentage of districts by DTP3 reported coverage<sup>e</sup>, 2013-2017



### DTP1-DTP3 dropout rate, 2013-2017<sup>d</sup>



Note: Dropout rate is calculated using WUENIC

### Immunization system characteristics, 2017

Sustained access to WHO accredited polio, measles, and rubella laboratories <sup>h</sup>	Yes
NITAG in place that meets six WHO criteria <sup>e</sup>	Yes
National system in place to monitor AEFIs <sup>e</sup>	Yes
Communication plan in place to respond to vaccine safety-related events <sup>e</sup>	Yes
Vaccine hesitancy assessment performed within last 5 years <sup>e</sup>	Yes
Mandatory proof of immunization at school entry <sup>e</sup>	Yes

Note: The six WHO NITAG criteria are 1. legislative or administrative basis for the advisory group; 2. formal written terms of reference; 3. at least five different areas of expertise represented among core members; 4. at least one meeting per year; 5. circulation of the agenda and background documents at least one week prior to meetings; 6. mandatory disclosure of any conflict of interest

## Vaccine stockouts by administrative level<sup>e,i</sup>, 2013-2017

	2013	2014	2015	2016	2017
BCG	No	No	Both	No	No
DTP	No	No	No	No	No
HepB	No	No	No	No	No
Hib	No	No	No	No	No
Pneumo	No	No	No	No	No
Rota	No	No	No	No	No
OPV	No	No	No	No	No
IPV	No	NR	Both	Both	Both
Measles	No	No	No	No	No
HPV	*	*	*	NR	Both
TT	NR	NR	NR	NR	NR

**Legend:**

- No stockout
- Subnational level stockout only
- National level stockout only
- Stockout at both levels
- NR
- ND

\*Data on HPV stockouts have only been collected in JRF since 2016

## Abbreviations

AEFI	Adverse event following immunization	MCV1	measles-mumps-rubella vaccine, first dose
BCG	Bacille Calmette-Guerin vaccine for tuberculosis	MCV2	measles-mumps-rubella vaccine, second dose
CRS	congenital Rubella Syndrome	MMR	measles-mumps-rubella vaccine
DT	diphtheria-tetanus-containing vaccine	ND	Data not available
DTP	diphtheria-tetanus-pertussis-containing vaccine	NITAG	National Immunization Technical Advisory Group
DTP1	diphtheria-tetanus-pertussis-containing vaccine, first dose	NNI	No NITAG at time of vaccine introduction
DTP3	diphtheria-tetanus-pertussis-containing vaccine, third dose	NR	Not relevant as vaccine not included in immunization schedule
GNI	Gross national income	OPV	oral polio vaccine
HepB	hepatitis B	PCV	pneumococcal conjugate vaccine
HepB3	hepatitis B vaccine, third dose	PCV3	pneumococcal conjugate vaccine , third dose
HepB-BD	hepatitis B vaccine, birth dose	Pol3	polio-containing vaccine, third dose
Hib	Haemophilus influenzae type b	RCV1	rubella-containing vaccine, first dose
Hib3	Haemophilus influenzae type b vaccine, third dose	Rotac	rotavirus vaccine-complete series
HPV	human papillomavirus	Td	tetanus-diphtheria-containing vaccine
IPV	inactivated polio vaccine	TT	tetanus toxoid vaccine
MCV	measles-containing vaccine	W,M,Y	Weeks, Months, Years

## Data sources

- a European Regional Commission for Certification of Poliomyelitis eradication (RCC) meeting report: [www.euro.who.int/32ndRCC](http://www.euro.who.int/32ndRCC)
- b European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: [www.euro.who.int/7thRVC](http://www.euro.who.int/7thRVC)
- c European Vaccine Action Plan 2015-2020 Midterm report
- d WHO/UNICEF Estimates of National Immunization Coverage (WUENIC): ([http://www.who.int/immunization/monitoring\\_surveillance/data/en/](http://www.who.int/immunization/monitoring_surveillance/data/en/))
- e WHO/UNICEF Joint Reporting Form on immunization (JRF)
- f World Population Prospects: The 2017 Revision, New York, United Nations
- g World Bank, World Development Indicators
- h Polio Laboratory Network: [www.euro.who.int/poliolabnetwork](http://www.euro.who.int/poliolabnetwork) & Personal communication based on annual accreditation process of the European Measles and Rubella Laboratory Network
- i Communication with the country

## Map disclaimer

† The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.